Lotus Eye Hospital & Institute Ltd
Diversified Consumer Services | Small Cap
Lotus Eye Hospital & Institute Ltd demonstrates a mixed financial performance. The company shows strong solvency, indicating a healthy balance between debt and equity. Efficiency ratios highlight effective inventory and receivables management, but fixed asset and capital turnover need improvement. While revenue growth is positive, declines in operating profit, EPS, and net income growth raise concerns about long-term sustainability. The company's interest coverage is strong, but dividend coverage is weak. Profitability metrics, such as gross profit margin, ROCE, ROE, and operating margin, are robust, but ROA is just average. Overall, the company exhibits financial strengths in solvency, efficiency and profitability but needs to address weaknesses in growth and financial management to ensure sustained financial health.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsOvervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio4.80
- Financial Ratio4.00
- Profitability Ratio9.60
- Efficiency Ratio7.33
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Lotus Eye Hospital & Institute Ltd demonstrates a mixed financial performance. The company shows strong solvency, indicating a healthy balance between debt and equity. Efficiency ratios highlight effective inventory and receivables management, but fixed asset and capital turnover need improvement. While revenue growth is positive, declines in operating profit, EPS, and net income growth raise concerns about long-term sustainability. The company's interest coverage is strong, but dividend coverage is weak. Profitability metrics, such as gross profit margin, ROCE, ROE, and operating margin, are robust, but ROA is just average. Overall, the company exhibits financial strengths in solvency, efficiency and profitability but needs to address weaknesses in growth and financial management to ensure sustained financial health.
Overall Valuation Score
P/E RATIO (TTM)
369.59
Industry Median
23.43
Small Cap Median
23.43
P/E RATIO
328.53
P/B RATIO
4.05
Industry Median
1.98
Small Cap Median
1.98
P/S RATIO
4.96
Industry Median
2.99
Small Cap Median
2.99
Others
PEG RATIO
-25.67
EV/EBITDA RATIO
50.83
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹118.27 as on Jun 15, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company shows positive revenue and asset growth, but declines in operating profit, EPS, and net income growth are concerning. While revenue growth indicates expanding market presence, declining profitability metrics suggest rising costs or inefficiencies. Focus on cost management and operational efficiency is needed to translate revenue growth into improved profitability.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 20.25 | 20.9 | 2.49 | 2.8 | 8.4 |
| Operating Profit Growth Rate | 63.54 | 29.73 | -13.67 | -46.3 | -5.06 |
| Earnings Per Share (EPS) Growth | 90.67 | 37.06 | -28.57 | -74.29 | -88.89 |
| Asset Growth Rate | 4.02 | 2.56 | 5.46 | 4.41 | 18.73 |
| Net Income Growth Rate | 89.81 | 36.91 | -28.68 | -74.57 | -89.19 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial metrics present a mixed picture. While capital expenditures are well-managed, adjusted EPS, cash EPS, book value per share, and dividend per share are low. The careful management of capital expenditures is commendable, the poor performance in other financial metrics might be concerning. Efforts to improve profitability and shareholder value are needed.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 1.43 | 1.96 | 1.4 | 0.36 | 0.04 |
| Cash Earnings Per Share (Cash EPS) | 2.63 | 3.39 | 3.19 | 1.8 | 1.84 |
| Book Value Per Share | 26.25 | 27.68 | 28.56 | 28.85 | 28.91 |
| Dividend Per Share (DPS) | 0.5 | 0.5 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 4.7 | 3.1 | 5.5 | 4.8 | 12.9 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company demonstrates good profitability, with strong gross profit margin, ROCE, ROE, operating margin, and net margin. These ratios indicate effective cost management and pricing strategies. Above-average profitability enhances the company's ability to reinvest in growth initiatives. Maintaining these high profitability levels is essential for long-term financial health.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 8.79 | 9.99 | 6.02 | 1.11 | -0.69 |
| Return on Capital Employed (ROCE) | 7.91 | 10.25 | 7.07 | 2.99 | 1.16 |
| Return on Equity (ROE) | 5.46 | 7.09 | 4.9 | 1.23 | 0.13 |
| Return on Assets (ROA) | 9.61 | 12.16 | 9.95 | 5.12 | 4.09 |
| Operating Margin | 15.22 | 16.33 | 13.76 | 7.18 | 6.29 |
| Net Margin | 7.66 | 8.68 | 6.04 | 1.49 | 0.15 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company demonstrates good efficiency in inventory and receivables management, but its fixed asset and capital turnover are low. Efficient inventory and receivables management ensures smooth operations and quick conversion of sales into cash. However, the company is not using its fixed assets or capital very efficiently. Addressing this could improve overall profitability and operational effectiveness.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 0.88 | 1.06 | 0.99 | 0.92 | 0.82 |
| Inventory Turnover Ratio | 17.35 | 16.6 | 15.1 | 13.92 | 14.12 |
| Receivables Turnover Ratio | 57.21 | 52.55 | 39.67 | 38.41 | 42.46 |
| Days Sales in Inventory Ratio | 21.04 | 21.99 | 24.17 | 26.22 | 25.85 |
| Receivable Days | 6.38 | 6.95 | 9.2 | 9.5 | 8.6 |
| Capital Turnover Ratio | 0.7 | 0.81 | 0.8 | 0.78 | 0.72 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company has a strong interest coverage ratio but a weak equity dividend coverage ratio. The strong interest coverage ensures the company can easily meet its interest obligations. The low dividend coverage, however, indicates that the company is not using equity to pay dividends. Improving dividend coverage could enhance investor confidence.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 20.48 | 29.25 | 21.05 | 3.88 | 0.94 |
| Equity Dividend Coverage Ratio | 2.87 | 3.92 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency, with a low debt ratio and debt-to-equity ratio, coupled with a high equity ratio. This indicates a solid financial structure with minimal reliance on debt. The company's assets are largely financed by equity, providing a stable base for operations. The healthcare industry benefits from such stability, especially during economic downturns.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.02 | 0.01 | 0.02 | 0.05 | 0.2 |
| Debt to Equity Ratio | 0.02 | 0.01 | 0.02 | 0.05 | 0.25 |
| Equity Ratio | 0.98 | 0.99 | 0.98 | 0.95 | 0.8 |
| Debt To Asset Ratio | 0.02 | 0.01 | 0.02 | 0.05 | 0.18 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, as indicated by the very low current, quick, and cash ratios. Because of the healthcare sector's reliance on consistent cash flow, this may cause some issues. The company's capacity to meet its short-term commitments may be hampered by its low liquidity ratios. This necessitates careful monitoring of cash flow and working capital, despite the industry's generally stable demand.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 3.05 | 3.85 | 2.93 | 2.52 | 2.12 |
| Quick Ratio | 2.65 | 3.29 | 2.4 | 1.9 | 1.63 |
| Cash Ratio | 1.54 | 1.71 | 1.15 | 0.68 | 0.49 |
| Operating Cash Flow Ratio | 0.77 | 0.89 | 0.93 | 0.44 | 0.38 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Vaidya Sane Ayurved Laboratories Ltd | 7.72 | 20.63 | Undervalued | 15.00 | 4.69 | 9.00 |
| 2 | Maitreya Medicare Ltd | 7.34 | -40.14 | Neutral | -0.46 | -1.96 | -2.47 |
| 3 | Lotus Eye Hospital & Institute Ltd | 6.07 | 328.53 | Overvalued | 3.38 | 0.04 | 0.08 |
| 4 | Nephro Care India Ltd | 5.69 | 33.82 | Neutral | 8.32 | 2.04 | 3.37 |
The management of Lotus Eye Hospital & Institute Ltd faces challenges in maintaining profitability and investor confidence. While the company has shown revenue growth, there are concerns about declining profit growth and a significant decrease in promoter holding. The management's effectiveness is assessed as mixed.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (2014-2025) | Positive | Demonstrates consistent revenue growth. |
| CONS | Compounded Profit Growth (TTM) | -75% | Indicates significant recent decline. |
| CONS | Promoter Holding Change (Mar 2023 to Mar 2025) | -17.95% | Raises concerns about long-term strategic alignment. |
| CONS | ROCE % (Mar 2025) | 2.79% | Shows low returns on capital. |
Financial Performance & Growth
The sales growth shows some positive trends, but profit growth is a concern. Compounded Sales Growth shows positive growth. But Compounded Profit Growth is declining.
| Metric | 10 Years | 5 Years | 3 Years | TTM |
|---|---|---|---|---|
| Compounded Sales Growth | 5% | 4% | 8% | 3% |
| Compounded Profit Growth | 9% | -13% | -38% | -75% |
Quarterly results indicate fluctuating OPM %, with a recent decline to -1.48% in Mar 2025. YOY Sales Growth % has been inconsistent, ranging from -2.60% to 5.79% in recent quarters.
Capital Efficiency & Returns
The ROCE % has declined to 2.79% in Mar 2025. ROE is also low, with a last year value of 1%. This suggests that the company is not generating high returns on its capital or equity.
| Metric | Mar 2014 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| ROCE % | 0.27% | 3.63% | 7.91% | 10.25% | 7.07% | 2.79% |
Financial Health & Prudence
There is an increase in borrowings in Mar 2025.
| Metric | Mar 2014 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Borrowings | 0.18 | 0.29 | 1.24 | 0.67 | 1.11 | 3.43 |
Shareholding & Ownership Structure
There has been a significant decrease in promoter holding from 58.17% in Mar 2023 to 40.22% in Mar 2025.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 58.17% | 58.44% | 57.58% | 56.58% | 41.40% | 40.24% | 40.03% | 40.14% | 40.22% |
The risk assessment for Lotus Eye Hospital & Institute Ltd is rated as Orange, indicating moderate risk. The primary concern is the segment performance volatility, evidenced by fluctuating quarterly sales and profit growth. The significant decrease in promoter holding increases risks associated with strategic direction and investor confidence. Working capital management is efficient. Overall, the company faces notable risks requiring careful monitoring.
Segment performance volatility
Quarterly results show volatility in both sales and profit growth. The YOY Sales Growth % has fluctuated, and the YOY Profit Growth % shows significant variations, including negative values.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YOY Sales Growth % | 0.00% | 100.51% | 9.71% | 4.57% | 5.68% | 5.90% | 7.34% | -0.91% | -2.60% | 2.55% | 1.41% | 1.83% | 5.79% |
| YOY Profit Growth % | -50% | 785% | -28% | -17% | 18% | 1% | -7% | -42% | -95% | -55% | -88% | -136% | 733% |
Foreign exchange or interest rate exposure
The company's interest expenses have increased from 0.20 in Mar 2024 to 0.36 in Mar 2025.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Interest | 0.21 | 0.20 | 0.20 | 0.36 |
Working capital management
The Cash Conversion Cycle has been negative in recent years.
| Metric | Mar 2014 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Cash Conversion Cycle | 41.14 | -39.78 | -75.37 | -10.74 | -3.72 | 20.82 |
Contingent liability evaluation
There is no specific data available on contingent liabilities.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe